Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

3.190 +0.030 (+0.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 361,838
Open 3.190
Bid (Size) 3.060 (3)
Ask (Size) 3.200 (1)
Prev. Close 3.160
Today's Range 3.160 - 3.275
52wk Range 2.455 - 4.145
Shares Outstanding 83,399,377
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
-6.7%
-6.7%
1 Month
+16.4%
+16.4%
3 Month
+1.9%
+1.9%
6 Month
+2.9%
+2.9%
1 Year
-9.6%
-9.6%

More News

Read More
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Top movers in Wednesday's pre-market session
Via Chartmill
Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors
From On Behalf of The Radoff-JEC Group
Via Business Wire
Atea Pharmaceuticals Issues Statement Regarding Director Nominations
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Announces Presentation of Bemnifosbuvir Preclinical Data at the 38th International Conference on Antiviral Research (ICAR) 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial
Via Benzinga
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Earnings Scheduled For March 6, 2025
Via Benzinga
Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study
Via Benzinga
Exposures COVID-19
Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire
Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
From Atea Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Atea Pharmaceuticals, Inc. - common stock publicly traded?
Yes, Atea Pharmaceuticals, Inc. - common stock is publicly traded.
What exchange does Atea Pharmaceuticals, Inc. - common stock trade on?
Atea Pharmaceuticals, Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Atea Pharmaceuticals, Inc. - common stock?
The ticker symbol for Atea Pharmaceuticals, Inc. - common stock is AVIR on the Nasdaq Stock Market
What is the current price of Atea Pharmaceuticals, Inc. - common stock?
The current price of Atea Pharmaceuticals, Inc. - common stock is 3.190
When was Atea Pharmaceuticals, Inc. - common stock last traded?
The last trade of Atea Pharmaceuticals, Inc. - common stock was at 06/16/25 04:00 PM ET
What is the market capitalization of Atea Pharmaceuticals, Inc. - common stock?
The market capitalization of Atea Pharmaceuticals, Inc. - common stock is 266.04M
How many shares of Atea Pharmaceuticals, Inc. - common stock are outstanding?
Atea Pharmaceuticals, Inc. - common stock has 266M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.